Ken Griffin Immutep LTD Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immutep LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 5,500 shares of IMMP stock, worth $11,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,500

Previous 2,000 175.0%

Holding current value

$11,825

Previous $4,000 200.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.11 - $2.89 $27,288 - $37,376	12,933 New	12,933 $30,000
Q3 2023 Nov 14, 2023	SELL	$1.75 - $2.37 $7,332 - $9,930	-4,190 Reduced 49.17%	4,332 $8,000
Q2 2023 Aug 14, 2023	SELL	$1.54 - $2.62 $127,980 - $217,732	-83,104 Reduced 90.7%	8,522 $17,000
Q1 2023 May 15, 2023	BUY	$1.63 - $2.06 $117,549 - $148,558	72,116 Added 369.64%	91,626 $153,000
Q4 2022 Feb 14, 2023	SELL	$1.71 - $2.53 $17,019 - $25,181	-9,953 Reduced 33.78%	19,510 $34,000

Q3 2022 Nov 14, 2022	BUY	$1.71 - $2.29 $14,452 - $19,355	8,452 Added 40.23%	29,463 $46,000
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.09 $4,470 - $7,048	2,281 Added 12.18%	21,011 $43,000
Q1 2022 May 16, 2022	SELL	$2.3 - $3.61 $101,963 - $160,038	-44,332 Reduced 70.3%	18,730 $51,000
Q4 2021 Feb 14, 2022	BUY	$3.09 - $4.81 $19,674 - $30,625	6,367 Added 11.23%	63,062 $206,000
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.39 $24,846 - $34,408	7,838 Added 16.04%	56,695 $220,000
Q2 2021 Aug 16, 2021	BUY	$3.02 - $5.21 $147,548 - $254,544	48,857 New	48,857 $189,000
Q2 2020 Aug 14, 2020	SELL	$0.67 - $1.31 $18,976 - $37,103	-28,323 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$0.72 - $3.03 $20,392 - $85,818	28,323 New	28,323 $20,000

Others Institutions Holding IMMP

# of Institutions

Shares Held

2.28M

Call Options Held

6.7K

Put Options Held

114K

View Full List

About IMMUTEP Ltd

Ticker IMMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,000
Market Cap $186M
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...

More about IMMP

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account